Iterion Therapeutics

📍 Houston, United States🗓 Founded 2014👥 13 employees💰 Last funded Dec 2020
Biotechnology Research🌐 iteriontherapeutics.com
Website LinkedIn
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The companys lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Canada
1
United States
1
Frequently asked questions
Who invested in Iterion Therapeutics?
Iterion Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Iterion Therapeutics last raise funding?
The most recent investment in Iterion Therapeutics recorded on gritt.io was in December 2020.
When was Iterion Therapeutics founded?
Iterion Therapeutics was founded in 2014.
What industry is Iterion Therapeutics in?
Iterion Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Iterion Therapeutics based?
Iterion Therapeutics is headquartered in Houston, United States.